Summit Therapeutics Inc. SMMT
Free cash flow down to -$323.6M
XBRL, from each 10-KThe latest figures
Price and key numbers
All key numbers (26, from the latest 10-K and 10-Q)
- EPS (ttm)
- -1.06
- Sales (ttm)
- -
- Net income (ttm)
- -832.7M
- Sales growth
- -
- EPS growth
- -
- Sales Q/Q
- -
- Free cash flow
- -526.9M
- Gross margin
- -
- Oper. margin
- -
- Net margin
- -
- FCF margin
- -
- ROE
- -147.5%
- ROA
- -120.2%
- R&D / sales
- -
- Dividend
- -
- Debt/Eq
- -
- Curr. ratio
- 5.99
- Cash
- 150.8M
- Op. cash flow (ttm)
- -525.2M
- Quick ratio
- 5.99
- FCF after stock pay
- -1.1B
- Goodwill / assets
- 0.3%
- Shares out.
- 799.8M
- Shares Y/Y
- +4.1%
- Book / share
- 0.71
- Cash / share
- 0.19
Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.
Revenue and net income, FY2019 to FY2024
Each fiscal year from its own 10-K · XBRL
From XBRL in each 10-K. Hover a bar for the line item and filing.
What the balance sheet holds, per share
Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used
Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.
SMMT against Health care peers
Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.
| Company | Revenue (ttm) | Sales growthFY | Gross marginttm | Net marginttm | ROEttm | FCF marginttm | Debt / equitylatest |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics Inc. | - | - | - | - | -147.5% | - | - |
| ROIV Roivant Sciences Ltd. | $41.1M | -71.6% | - | -838.2% | -8.6% | -81.2% | - |
| IDYA IDEAYA Biosciences, Inc. | $36.5M | - | - | - | -38.5% | -957.4% | - |
| CRSP CRISPR Therapeutics AG | $25.2M | -90.6% | - | - | -27.7% | - | 0.36 |
| CGON CG Oncology, Inc. | $6.2M | +255% | - | - | -24.0% | - | 0.00 |
| SRRK Scholar Rock Holding Corp | $570K | - | - | - | - | - | 1.16 |
Profitability
-
Return on equity below 15%-147.5%
-
A profit in 1 of 6 years
Balance sheet
-
Interest covered less than 5 timesOperating income is -26.0× interest expense
-
Current assets cover current liabilitiesCurrent ratio 5.99
Cash and shareholders
-
Free cash flow positive in 0 of 6 years−$142.2M last year
-
Share count up over 5 years+15.9%
Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.
Income statement, balance sheet and cash flow
Statements · XBRL, each 10-K and 10-Q
SMMT's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 7. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.
Income statement
From EDGAR| FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 57.1M | 860K | 1.8M | 705K | 0 | 0 | - |
| R&D | 52.0M | 53.3M | 85.4M | 52.0M | 59.5M | 150.8M | 537.7M |
| SG&A | 17.0M | 19.2M | 23.6M | 26.7M | 29.3M | 60.2M | 556.8M |
| Operating income | 5.4M | -53.2M | -86.2M | -72.1M | -609.6M | -226.0M | - |
| Interest expense | 620K | 255K | 242K | 4.4M | 16.5M | 8.7M | 0 |
| Pretax income | 9.1M | -52.9M | -88.6M | -78.8M | -614.9M | -221.3M | -1.1B |
| Income tax | -1.8M | -213K | 0 | - | 0 | 0 | 0 |
| Net income | 10.9M | -52.7M | -88.6M | -78.8M | -614.9M | -221.3M | -1.1B |
| EPS (diluted) | 0.63 | -0.76 | -0.67 | -0.41 | -0.99 | -0.31 | -1.44 |
| Diluted shares | 17.2M | 69.5M | 131.7M | 193.3M | 619.6M | 718.5M | 747.7M |
| Depreciation & amortization | 409K | 302K | 330K | 349K | 198K | 89K | 146K |
| EBITDA | 5.8M | -52.9M | -85.9M | -71.7M | -609.5M | -225.9M | - |
| Operating margin | 9.4% | -6185.2% | -4764.3% | -10225.4% | - | - | - |
| Net margin | 19.0% | -6127.6% | -4897.8% | -11174.8% | - | - | - |
| Revenue growth | - | - | +110% | -61.0% | -100% | - | - |
Balance sheet
From EDGAR| FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|
| Cash | 35.2M | 66.4M | 71.8M | 348.6M | 71.4M | 104.9M | 225.3M |
| Short-term investments | - | - | - | 0 | 114.8M | 307.5M | 488.2M |
| Receivables | 6.1M | 331K | 1.5M | 349K | 0 | - | - |
| Current assets | 61.3M | 87.7M | 97.3M | 656.7M | 189.7M | 423.8M | 720.3M |
| Property & equipment | 649K | 725K | 694K | 906K | 204K | 254K | 1.1M |
| Goodwill | 2.0M | 2.0M | 2.0M | 1.8M | 1.9M | 1.9M | 2.0M |
| Other intangible assets | 13.9M | 11.5M | 10.4M | 0 | 0 | 0 | - |
| Total assets | 79.6M | 102.5M | 113.4M | 664.2M | 202.9M | 435.6M | 751.2M |
| Accounts payable | 5.8M | 6.1M | 4.4M | 355K | 2.7M | 4.6M | 20.3M |
| Current liabilities | 17.2M | 19.9M | 25.6M | 38.8M | 20.4M | 41.7M | 73.0M |
| Total debt | - | - | - | 514.3M | 100.0M | 0 | - |
| Total liabilities | 23.8M | 23.0M | 30.1M | 537.5M | 125.3M | 46.8M | 92.3M |
| Shareholders' equity | 57.6M | 79.5M | 83.3M | 126.7M | 77.7M | 388.7M | 658.9M |
| Retained earnings | -130.9M | -210.9M | -299.5M | -378.3M | -993.3M | -1.2B | -2.3B |
Cash flow
From EDGAR| FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -35.1M | -48.1M | -72.6M | -41.6M | -76.8M | -142.1M | -322.9M |
| Capital spending | 157K | 421K | 306K | 624K | 128K | 139K | 657K |
| Free cash flow | -35.3M | -48.5M | -72.9M | -42.2M | -76.9M | -142.2M | -323.6M |
| Stock-based pay (added back) | 6.3M | 1.8M | 12.8M | 11.9M | 14.1M | 51.0M | 732.4M |
| Free cash flow after stock pay | -41.6M | -50.3M | -85.7M | -54.2M | -91.0M | -193.2M | -1.1B |
| Dividends paid | 0 | 0 | - | - | - | - | - |
| Investing cash flow | -331K | -421K | -306K | -624K | -587.8M | -205.3M | -174.3M |
| Financing cash flow | 44.5M | 50.6M | 77.9M | 620.2M | 86.5M | 381.2M | 617.5M |
Stock-based pay and leases
From EDGAR| FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|
| Stock-based pay (expense) | 6.3M | 1.8M | 12.8M | 11.9M | 14.1M | 51.0M | 732.4M |
| Stock-based pay / revenue | 11.0% | 205.3% | 707.8% | 1694.8% | - | - | - |
| Operating lease cost | 501K | 478K | 785K | 1.4M | 2.2M | 3.5M | 3.9M |
| Operating lease cash paid | 369K | 488K | 1.0M | 1.1M | 2.2M | 2.6M | 3.7M |
| Right-of-use assets | 1.4M | 554K | 2.8M | 4.2M | 5.9M | 7.1M | 20.6M |
| Operating lease liabilities | 1.3M | 465K | 2.8M | 4.5M | 6.1M | 7.2M | 20.9M |
From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.
Sources
Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.
Also
Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SMMT/export.csv") into a cell.